Menu

JHU Researchers Harmed Dogs, Animal Rights Group Argues

Stop Animal Exploitation Now issues a federal complaint against Johns Hopkins scientists, saying they messed up surgeries on nine animals.

Aug 15, 2019
Ashley Yeager

ABOVE: © ISTOCK.COM, SSHEPARD

An animal rights group called Stop Animal Exploitation Now has filed a federal complaint with the US Department of Agriculture against Johns Hopkins scientists for failed surgeries that led to euthanasia of nine dogs, the Baltimore Sun reported Tuesday (August 13). 

The Ohio-based group refers to a letter that Hopkins researchers sent to the National Institutes of Health about the termination of federally funded research on spinal cord stimulation as a treatment for a gastrointestinal disorder called gastroparesis. In 2017 and 2018, the researchers had planned surgeries on 19 dogs. Nine experienced complications, which resulted in euthanizing them for humane reasons, according to the Sun.

It is not the first complaint the group has filed against the university. In February, it sent a complaint to the USDA about a marmoset that was crushed in a cage door. After an inspection by the USDA, the agency cited the lab for “unqualified personnel.” 

“It is quite clear that something is rotten at Johns Hopkins University,” Michael Budkie, cofounder of the animal rights group, tells the Sun. “Causing paralysis in dogs and crushing a marmoset monkey in a cage door are not only immensely cruel, but these incidents also clearly demonstrate that bungling JHU staff is unqualified.”

In the federal complaint, the animal rights group says Hopkins researchers violated the Animal Welfare Act, and it seeks $10,000—the maximum penalty—for each harmed dog. 

“The care of animals involved in our research is incredibly important to us,” Kim Hoppe, a spokeswoman for Hopkins, says in a statement, according to the Sun. “We rigorously adhere to all state and federal animal welfare requirements and guidelines, including closely monitoring all animal research and providing regular reports to government agencies that oversee such research.”

She notes that the university obeys USDA regulations and other government and institutional guidelines and policies and that it reported the incident to the National Institutes of Health’s Office of Laboratory Animal Welfare. After the study ended, she adds, the remaining dogs were adopted.

See “Animals Start New Lives After Time in the Lab 

Ashley Yeager is an associate editor at The Scientist. Email her at ayeager@the-scientist.com.

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Download this application note to learn how the ACEA xCELLigence system can evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors and monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios.
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Watch this webinar to learn how Dr. Cara Haymaker and her team are assessing the reactivity of tumor-infiltrating lymphocytes and modulating the mechanisms of resistance to therapy and exploring biomarkers involved in the response.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs